Kuramitsu Madoka, Hamaguchi Isao, Takuo Mizukami, Masumi Atsuko, Momose Haruka, Takizawa Kazuya, Mochizuki Masayo, Naito Seishirou, Yamaguchi Kazunari
Department of Safety Research on Blood and Biological Products, National Institute of Infectious Disease, Musashimurayama, Tokyo, Japan.
Br J Haematol. 2008 Feb;140(3):348-59. doi: 10.1111/j.1365-2141.2007.06930.x.
The gene encoding ribosomal protein S19 (RPS19) is one of the responsible genes for Diamond-Blackfan anaemia (DBA), a congenital erythroblastopenia. Although haplo-insufficiency of RPS19 has been suggested to be the onset mechanism underlying the pathogenesis of DBA, the sequential mechanism has not been elucidated. In order to analyse the consequences of the missense mutation of RPS19 specific for DBA patients, we made mutated RPS19 expression vectors. Twelve C-terminally Flag-tagged missense mutants were exogenously expressed from retroviral vectors and analysed by Western blot analysis and flow cytometry. When these 12 mutants were expressed in the erythro-leukaemic cell lines K562 and human bone marrow CD34(+) cells, almost all of the mutant proteins (except for G120R) were unstable, and the levels of mutated RPS19 protein were significantly low. To address the effect of deficient RPS19 expression on cell proliferation, RPS19 was downregulated by siRNA. Repressive expression of RPS19 in human CD34(+) cells produced an elevated number of cells at G0 and induced erythroid progenitor-specific defects in BM cells. These results suggest that abnormal ribosomal biogenesis causes inadequate cell cycle arrest in haematopoietic progenitors, and that, subsequently, erythroid progenitors are specifically hampered. These in vitro phenotypes of genetically manipulated CD34(+) cells mimic DBA pathogenesis.
编码核糖体蛋白S19(RPS19)的基因是先天性红细胞生成减少症——钻石黑范贫血(DBA)的致病基因之一。尽管RPS19单倍体不足被认为是DBA发病机制的起始机制,但其后续机制尚未阐明。为了分析DBA患者特有的RPS19错义突变的后果,我们构建了突变型RPS19表达载体。12个C末端带有Flag标签的错义突变体从逆转录病毒载体中外源表达,并通过蛋白质免疫印迹分析和流式细胞术进行分析。当这12个突变体在红白血病细胞系K562和人骨髓CD34(+)细胞中表达时,几乎所有突变蛋白(除G120R外)都不稳定,且突变型RPS19蛋白水平显著降低。为了研究RPS19表达缺陷对细胞增殖的影响,通过小干扰RNA(siRNA)下调RPS19的表达。RPS19在人CD34(+)细胞中的抑制性表达导致处于G0期的细胞数量增加,并诱导骨髓细胞中红系祖细胞特异性缺陷。这些结果表明,异常的核糖体生物合成导致造血祖细胞的细胞周期阻滞不足,随后红系祖细胞受到特异性阻碍。基因操作的CD34(+)细胞的这些体外表型模拟了DBA的发病机制。